

Correction

BriTROC investigators

DOI:

[10.1038/s41416-019-0433-6](https://doi.org/10.1038/s41416-019-0433-6)

License:

Creative Commons: Attribution (CC BY)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

BriTROC investigators 2019, 'Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium', *British Journal of Cancer*, vol. 120, no. 8, 868, pp. 868. <https://doi.org/10.1038/s41416-019-0433-6>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked for eligibility: 07/05/2019

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.



CORRECTION

Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium

T Goranova¹, D Ennis², A M Piskorz¹, G Macintyre¹, L A Lewsley³, J Stobo³, C Wilson³, D Kay⁴, R M Glasspool⁵, M Lockley^{6,7}, E Brockbank⁶, A Montes⁸, A Walther⁹, S Sundar¹⁰, R Edmondson¹¹, G D Hall¹², A Clamp¹³, C Gourley¹⁴, M Hall¹⁵, C Fotopoulou¹⁶, H Gabra¹⁶, S Freeman¹⁷, L Moore¹⁷, M Jimenez-Linan¹⁷, J Paul³, J D Brenton^{1,17} and I A McNeish^{2,5} on behalf of the BriTROC investigators

British Journal of Cancer (2019) 120:868; <https://doi.org/10.1038/s41416-019-0433-6>

Correction to: *British Journal of Cancer* **116**,1294–1301; <https://doi.org/10.1038/bjc.2017.86>; published online 30 March 2017

This article was originally published under a CC BY NC SA License, but has now been made available under a CC BY 4.0 License.

appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give

© The Author(s) 2019

¹Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK; ²Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK; ³Cancer Research UK Clinical Trials Unit, Glasgow G12 0YN, UK; ⁴Department of Radiology, Gartnavel General Hospital, Glasgow G12 0YN, UK; ⁵Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, UK; ⁶Barts Cancer Institute, London EC1M 6BQ, UK; ⁷University College Hospital, London WC1E 6BD, UK; ⁸Guy's Hospital, London SE1 9RT, UK; ⁹Bristol Haematology and Oncology Centre, Bristol BS2 8ED, UK; ¹⁰City Hospital, Birmingham B18 7QH, UK; ¹¹St Mary's Hospital, Manchester M13 9WL, UK; ¹²St James Hospital, Leeds LS9 7TF, UK; ¹³The Christie Hospital, Manchester M20 4BX, UK; ¹⁴Edinburgh Cancer Research Centre, Edinburgh EH4 2XR, UK; ¹⁵Mount Vernon Cancer Centre, Northwood HA6 2RN, UK; ¹⁶Imperial College, London W12 0HS, UK and ¹⁷Addenbrooke's Hospital, Cambridge CB2 0QQ, UK

Correspondence: J D Brenton (james.brenton@cruk.cam.ac.uk) or I A McNeish (iain.mcneish@glasgow.ac.uk)

Published online: 13 March 2019